Services and Solutions
With locations in the United States (New Jersey) and China (Shanghai, Suzhou, Nanjing, and Nantong), We offer a full range of discovery screening, preclinical development, and clinical drug metabolism and pharmacokinetics (DMPK) platforms and services.
-
In Vitro ADME
Learn More
In Vitro ADME
We have dedicated in vitro ADME teams for experiments and analysis, each offering first-class capabilities, high-throughput, and rapid, high-quality data delivery. The standard ADME assays are validated to ensure the accuracy and reliability of our experimental data.
-
In Vivo PK
Learn More
In Vivo PK
Offering rodent and large animal (non-rodent) PK studies, our protocols are designed specifically to fulfill client's needs and experiment purposes, including formulation screening, dose and sampling time point setting, administration route, and surgical models.
-
Met ID
Learn More
Met ID
We provide comprehensive MetID services, including preclinical in vitro and in vivo MetID, clinical human MetID (FIH, SAD, and MAD) and metabolites in safety testing (MIST) study, and metabolite biosynthesis and structural characterization.
-
Radiolabeled ADME
Learn More
Radiolabeled ADME
The radiolabeled in vivo ADME studies in WuXi AppTec DMPK include radiolabeled compound synthesis, [14C] and [3H] -labeled compound preclinical in vivo ADME (rat/mouse/dog/monkey/mini-pig), radiolabeled MetID, and human AME study service.
-
DMPK Bioanalysis
Learn More
DMPK Bioanalysis
With an experienced professional analysis team, advanced analytical instruments, whole-process digital management, and reliable quality control systems, we continuously empower our customers with high-efficiency and high-quality bioanalytical services from screening to clinical, including large and small molecule drugs, biomarkers, immunogenicity, and cell-based assays.
-
Novel Drug Modalities
Learn More
Novel Drug Modalities
Through extensive experience in novel drug modalities, we have accumulated comprehensive solutions and methodologies for different drug modalities including peptides, ADCs, PDCs, antibodies, oligonucleotides, mRNAs, PROTACs, and other drug molecules.
-
Therapeutic Areas
Learn More
Therapeutic Areas
We have set up specialized research teams mastering difficult experimental techniques to develop targeted research strategies in the areas of ophthalmic, transdermal, respiratory, neurosciences, anti-tumor, and anti-infection.
-
Featured Solutions
Learn More
Featured Solutions
Our featured solutions include compound management service, metabolite biosynthesis and structural characterization, radiolabeled compound synthesis, and high-throughput automation platforms.
Discuss Your Project
Speak with an expert about your upcoming project to see how we can help you
About WuXi AppTec DMPK
As a global DMPK service provider, we are committed to supporting all clients with high-quality data, precise R&D strategies, and excellent services to meet the unique needs of every client and become the preferred partner for DMPK studies.
18+
Years of experience
1,000+
Employees
1,600+
Global clients
1,500+
Successful IND filings supported
Why Choose Us?
Fast and Reliable Data Delivery
No lead time for in vitro and in vivo assays
Fast turnaround time
Meet IND and NDA requirements of FDA, NMPA, and EMA
Successfully pass over 15 years of audits
High-Throughput Automation Platforms
Fully automated in vitro ADME workstation
Fully automated bioanalysis sample pretreatment system
Automatic blood sampling and plasma separation system
Experienced and Professional Teams
Dedicated study director provides specialized project management
Professional teams dedicated to experiment design, implementation, and report delivery
High Standard Instruments and Facilities
AAALAC-accredited and intelligent animal facilities
High-precision bioanalytical and identification instruments
Integrated Service
Screening to IND filing, in vitro and in vivo
Routine small molecules and new modalities
High-efficiency cross-department collaboration
Stay Connected
Keep up with the latest news and insights.